Rna Diagnostics
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
21 St Clair Ave E Suite 701, Toronto, On...Phone Number
(416) 333-2931Website
www.rnadiagnostics.comRevenue
<$5 MillionIndustry
About Rna Diagnostics
Rna Diagnostics is a clinical-stage molecular diagnostics company focused on improving cancer care through its Veridapt DX predictive biomarker platform. This technology measures tumor response to cancer drugs, enabling physicians to make informed treatment decisions as early as five weeks into therapy. The company primarily targets oncologists, patients, and payers, offering actionable insights that lead to better patient outcomes and cost savings. While initially focused on primary breast cancer, the platform is applicable to any solid tumor and cancer drug therapy.Explore more
Rna Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Rna Diagnostics
Compare insights from companies similar to Rna Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Rna Diagnostics Tech Stack
A closer look at the technologies used by Rna Diagnostics
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rna Diagnostics
Sign Up For FreeTo access detailed company insights
Rna Diagnostics is a clinical-stage molecular diagnostics company focused on improving cancer care through its Veridapt DX predictive biomarker platform. This technology measures tumor response to cancer drugs, enabling physicians to make informed treatment decisions as early as five weeks into therapy. The company primarily targets oncologists, pa... Read More
